Microneedle‐Delivered PDA@Exo for Multifaceted Osteoarthritis Treatment via PI3K‐Akt‐mTOR Pathway
Advanced Science · 2024-11 · 11 (42)
DOI: 10.1002/advs.202406942 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 29.08.2024. Verfasst von Zihua Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, P. R. China. Hauptthemen laut MEDLINE: Osteoarthritis, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, Polymers. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Animal Health Care Ethics Committee of Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China, National Key R&D Program of China, Shanghai Committee of Science and Technology.
Abstract (Originalsprache)
Osteoarthritis (OA) is marked by cartilage deterioration, subchondral bone changes, and an inflammatory microenvironment. The study introduces the Microneedle‐Delivered Polydopamine‐Exosome (PDA@Exo MN), a therapeutic that not only preserves cartilage and promotes bone regeneration but also improves localized drug delivery through enhanced penetration capabilities. PDA@Exo MN shows strong reactive oxygen species (ROS) scavenging abilities and high biocompatibility, fostering osteogenesis and balancing anabolic and catabolic processes in cartilage. It directs macrophage polarization from M0 to the anti‐inflammatory M2 phenotype. RNA sequencing of treated chondrocytes demonstrates restored cellular function and activated antioxidant responses, with modulated inflammatory pathways. The PI3K‐AKT‐mTOR pathway's activation, essential for PDA@Exo's effects, is confirmed via bioinformatics and Western blot. In vivo assessments robustly validate that PDA@Exo MN prevents cartilage degradation and OA progression, supported by histological assessments and micro‐CT analysis, highlighting its disease‐modifying impact. The excellent biocompatibility of PDA@Exo MN, verified through histological (H&E) and blood tests showing no organ damage, underscores its safety and efficacy for OA therapy, making it a novel and multifunctional nanomedical approach in orthopedics, characterized by organ‐friendliness and biosecurity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, P. R. China.
- School of Medicine, Tongji University, Shanghai, 200092, P. R. China.
- Southern Medical University, Guangzhou, 510515, P. R. China.
- Department of Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P. R. China.
ORCID-Profile: Zihua Li, Yunfeng Yang
Förderung
- Animal Health Care Ethics Committee of Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China
- National Key R&D Program of China
- Shanghai Committee of Science and Technology
- Shanghai Tongji Hospital
- Shanghai Jiaotong University Ruijin Hospital
- National Key Research and Development Program of China
Zitieren
APA
Li, Z., Lu, H., Fan, L., Ma, X., Duan, Z., Zhang, Y., Fu, Y., Wang, S., Guan, Y., Yang, D., Chen, Q., Xu, T., & Yang, Y. (2024). Microneedle‐Delivered PDA@Exo for Multifaceted Osteoarthritis Treatment via PI3K‐Akt‐mTOR Pathway. Advanced Science, 11(42). https://doi.org/10.1002/advs.202406942
Vancouver
Li Z, Lu H, Fan L, Ma X, Duan Z, Zhang Y, et al. Microneedle‐Delivered PDA@Exo for Multifaceted Osteoarthritis Treatment via PI3K‐Akt‐mTOR Pathway. Advanced Science. 2024;11(42). doi:10.1002/advs.202406942
BibTeX
@article{Li2024,
author = {Li, Zihua and Lu, Hengli and Fan, Limin and Ma, Xiaoyi and Duan, Zhengwei and Zhang, Yiwei and Fu, Yuesong and Wang, Sen and Guan, Yonghao and Yang, Dong and Chen, Qingjing and Xu, Tianyang and Yang, Yunfeng},
title = {Microneedle‐Delivered PDA@Exo for Multifaceted Osteoarthritis Treatment via PI3K‐Akt‐mTOR Pathway},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {42},
doi = {10.1002/advs.202406942}
}
EUVIMED